NRAS mutant melanomas rarely harbour either mutations in, or silencing of the negative regulator of the PI3K pathway, phosphatase and tensin homologue and exhibit lower levels of constitutive AKT signalling than those with BRAF mutations36. This evidence concerns the gene NRAS and melanoma.